(S)-3-氨基-3-苯丙酸乙酯盐酸盐 | 167834-24-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-3-氨基-3-苯丙酸乙酯盐酸盐
• 中文别名: S-3-氨基-3-苯基丙酸乙酯盐酸盐；(3S)-3-氨基-3-苯基丙酸乙酯盐酸盐；(S)-3-氨基-3-苯基丙酸乙酯盐酸盐
• 英文名称: ethyl (S)-3-amino-3-phenylpropanoate hydrochloride
• 英文别名: ethyl (S)-3-amino-3-phenyl-propionate hydrochloride；(S)-Ethyl 3-amino-3-phenylpropanoate hydrochloride；ethyl (3S)-3-amino-3-phenylpropanoate;hydrochloride
• CAS: 167834-24-4
• 化学式: C₁₁H₁₅NO₂*ClH
• mdl: MFCD02259715
• 分子量: 229.707
• InChiKey: ATSZQDTVNRNXKB-PPHPATTJSA-N

物化性质

• 熔点：
  117 °C
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.38
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  29223900
• 危险品运输编号：
  UN2811
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存于阴凉干燥处。

SDS

Name:	(S)-3-Amino-3-Phenylpropanoic Acid Ethyl Ester Hydrochloride 95% Material Safety Data Sheet
Synonym:	None Known
CAS:	167834-24-4

Section 1 - Chemical Product MSDS Name:(S)-3-Amino-3-Phenylpropanoic Acid Ethyl Ester Hydrochloride 95% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
167834-24-4	(S)-3-Amino-3-Phenylpropanoic Acid Eth	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 167834-24-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 114 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H15NO2.HCl
Molecular Weight: 229.71

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 167834-24-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-3-Amino-3-Phenylpropanoic Acid Ethyl Ester Hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 167834-24-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 167834-24-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 167834-24-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：达泊西汀盐酸盐中间体

反应信息

• 作为反应物：
  描述：

  (S)-3-氨基-3-苯丙酸乙酯盐酸盐 在 sodium hypochlorite 、 sodium tetrahydroborate 、 2,2,6,6-四甲基哌啶氧化物 、 三乙酰氧基硼氢化钠 、 碳酸氢钠 、 sodium carbonate 、 sodium bromide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 反应 5.83h， 生成 马拉维若
  参考文献：
  名称：

  CCR-5受体拮抗剂Maraviroc（UK-427,857）的商业化路线的工艺研究和规模扩大

  摘要：

  已经开发了六步合成CCR-5受体拮抗剂Maraviroc（UK-427,857）（1）的途径，并在中试工厂中得到了证明。这条路线已经支持了四个试点战役，并产生了1的多千克数量。合成路线的持续发展已导致在稳定的工艺与吞吐量相比于原始合成的（海科克-Lewandowski的，SJ改善; Mawby，NJ;怀德，A。; Ahman，J. 。组织过程RES开发。 2008年，12，1094至1103年）。

  DOI：

  10.1021/op800062d
• 作为产物：
  描述：

  N-苄氧羰酰基-D-苯丙氨酸 在 palladium-carbon 作用下， 以 乙醇 为溶剂， 以5.05 g (70%)的产率得到(S)-3-氨基-3-苯丙酸乙酯盐酸盐
  参考文献：
  名称：

  Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom

  摘要：

  本发明涉及式I的螺环咪唑啉衍生物，其中E、V、W、X、R1和R2具有索引中指示的含义。式I的化合物是有价值的药用活性化合物，例如适用于治疗和预防炎症性疾病，如风湿性关节炎或过敏性疾病。式I的化合物还是白细胞粘附和迁移的抑制剂和/或整合素群中属于VLA-4粘附受体的拮抗剂。它们通常适用于治疗和预防由白细胞粘附和/或白细胞迁移不受欢迎的程度引起的疾病，或与之相关的疾病，或在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用发挥作用的疾病。该发明还涉及制备式I的化合物的方法、含有式I的药物制剂以及治疗这些疾病的方法。

  公开号：

  US06399643B1

文献信息

• [EN] Pan-Tropic Entry Inhibitors<br/>[FR] INHIBITEURS D'ENTRÉE PANTROPIQUE
  申请人：UNIV EMORY

  公开号：WO2019183133A1

  公开（公告）日：2019-09-26

  This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

  本公开涉及按照式(I)的化合物、盐、前药和含有该化合物的药物配方，用于治疗与CXCR4和CCR5相关的疾病。这些疾病可能包括病毒感染、异常细胞增殖、视网膜退化和炎症性疾病，或者这些化合物可以用作免疫刺激剂或免疫抑制剂。此外，这些化合物可以与另一种来自抗病毒药物或化疗药物的活性成分结合使用。
• Substituted 5-membered ring heterocycles, their preparation and their use
  申请人：Hoechst Aktiengesellschaft

  公开号：US05981492A1

  公开（公告）日：1999-11-09

  The present invention pertains to 5-ring heterocycles of general formula (I), wherein W, Y, Z, B, D, E and R as well as b, c, d, e, f, g, and h are as indicated in the description; to methods for preparing them, and to their use as inhibitors of platelet aggregation, metastasizing of carcinomatous cells and the attachment of osteoclasts to the bone surface. ##STR1##

  本发明涉及一般式（I）的5-环杂环化合物，其中W、Y、Z、B、D、E和R以及b、c、d、e、f、g和h如描述中所示；以及其制备方法，以及它们作为抑制血小板聚集、癌细胞转移和破骨细胞附着于骨表面的用途。
• Hydantoin compounds, salts thereof, processes for their preparation, and
  申请人：Hoechst Aktiengesellschaft

  公开号：US05939556A1

  公开（公告）日：1999-08-17

  The present invention relates to hydantoin derivatives of the formula I ##STR1## and which are intermediates for the preparation of pharmaceutical active compounds, their preparation and their use in the preparation of the active compounds.

  本发明涉及公式I的咪唑烷二酮衍生物，它们是制备药用活性化合物的中间体，以及它们的制备和在活性化合物的制备中的使用。
• Discovery of an Orally Active Non-Peptide Fibrinogen Receptor Antagonist Based on the Hydantoin Scaffold
  作者：Hans Ulrich Stilz、Wolfgang Guba、Bernd Jablonka、Melitta Just、Otmar Klingler、Wolfgang König、Volkmar Wehner、Gerhard Zoller

  DOI：10.1021/jm001068s

  日期：2001.4.1

  Antagonists of the platelet fibrinogen receptor (GP IIb/IIIa receptor) are expected to be a promising new class of antithrombotic agents. The binding of fibrinogen to the fibrinogen receptor depends on an Arg-Gly-Asp-Ser (RGDS) tetrapeptide recognition motif. Structural modifications of the RGDS lead have led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antagonist 44 (S 1197). Compound

  血小板纤维蛋白原受体（GP IIb / IIIa受体）的拮抗剂有望成为一种有前途的新型抗血栓药。纤维蛋白原与纤维蛋白原受体的结合取决于Arg-Gly-Asp-Ser（RGDS）四肽识别基序。RGDS导联的结构修饰导致发现了非肽RGD模拟GP IIb / IIIa拮抗剂44（S 1197）。化合物44以剂量依赖和可逆的方式抑制人和狗的血小板聚集以及125I-纤维蛋白原与ADP激活的人凝胶过滤的血小板和分离的GP IIb / IIIa的结合，K（i）的K（i）值为9 nM和0.17 nM ， 分别。使用QXP进行药效团映射的程序以及应用GRID / GOLPE方法进行的3D-QSAR分析产生了稳定的，相当可预测的模型，并揭示了对绑定非常重要的结构特征。在乙内酰脲核和C-末端的疏水取代均增加了对血纤蛋白原受体的亲和力。结晶乙酯前药48（HMR 1794）是一种口服活性抗血栓药，是治疗人类血栓性疾病的有前途的候选药物。
• [EN] ANTITHROMBOTIC COMPOUNDS WITH DUAL FUNCTION<br/>[FR] COMPOSES ANTITHROMBOTIQUES A FONCTION DUALE
  申请人：UNIV LJUBLJANA

  公开号：WO2005051934A1

  公开（公告）日：2005-06-09

  The present invention comprises compounds of the general formula (I) : and pharmaceutically acceptable salts thereof, wherein the substituents have in the description specified meaning. The compounds are used as antithrombotic agents possessing inhibitory activity on platelet aggregation and simultaneous thrombin and/or factor Xa inhibititory activity.

  本发明包括一般式(I)的化合物及其药学上可接受的盐，其中取代基具有描述中指定的含义。这些化合物被用作抗血栓药物，具有抑制血小板聚集和同时抑制凝血酶和/或因子Xa的活性。